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Background: Aggregated forms of amyloid-β (Aβ) peptides are important triggers for microglial activation, which is
an important pathological component in the brains of Alzheimer’s patients. Cu(II) ions are reported to be coordinated
to monomeric Aβ, drive Aβ aggregation, and potentiate Aβ neurotoxicity. Here we investigated whether Cu(II) binding
modulates the effect of Aβ on microglial activation and the subsequent neurotoxicity.
Methods: Aβ peptides were incubated with Cu(II) at an equimolar ratio to obtain the Cu(II)-Aβ complex. Primary and
BV-2 microglial cells were treated with Cu(II)-Aβ, Aβ, or Cu(II). The tumor necrosis factor-α (TNF-α) and nitric oxide levels
in the media were determined. Extracellular hydrogen peroxide was quantified by a fluorometric assay with Amplex
Red. Mitochondrial superoxide was detected by MitoSOX oxidation.
Results: Incubation of Cu(II) with Aβ confers different chemical properties on the resulting complex. At the subneurotoxic
concentrations, Cu(II)-Aβ (but not Aβ or Cu(II) alone) treatment induced an activating morphological phenotype
of microglia and induced the microglial release of TNF-α and nitric oxide as well as microglia-mediated neuronal
damage. Cu(II)-Aβ-triggered microglial activation was blocked by nuclear factor (NF)-κB inhibitors and was accompanied
with NF-κB activation. Moreover, Cu(II)-Aβ induced hydrogen peroxide release, which was not affected by NADPH oxidase
inhibitors. Mitochondrial superoxide production was increased after Cu(II)-Aβ stimulation. N-acetyl-cysteine, a scavenger of
reactive oxygen species (ROS), inhibited Cu(II)-Aβ-elicited microglial release of TNF-α and nitric oxide as well as the
microglia-mediated neurotoxic effect.
Conclusion: Our observations suggest that Cu(II) enhances the effect of Aβ on microglial activation and the subsequent
neurotoxicity. The Cu(II)-Aβ-triggered microglial activation involves NF-κB activation and mitochondrial ROS production.
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Neuroinflammation, characterized by excessive glial acti-
vation and overproduction of proinflammatory cytokine
and chemokines, plays a critical role in the pathogenesis
of neurodegeneration in Alzheimer’s disease (AD) and
related neurodegenerative disorders [1]. Inhibition of glial
activation is shown to improve synaptic dysfunction and
behavioral deficits in AD animal models [2].
Amyloid-β (Aβ) peptides are key molecules in AD path-
ology as they aggregate to form amyloid plaques, the pri-
mary neuropathological hallmarks of AD [3]. Aggregated
Aβ peptides, in the forms of fibrils and oligomers, are* Correspondence: lijuanpharm@163.com; yaoli@shsmu.edu.cn
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mulating evidence demonstrates that the redox-active
Cu(II) ions can be coordinated to the histidine (His6,
His13, and His14) or Tyr10 of monomeric Aβ. This coord-
ination leads to formation of the Cu(II)-Aβ complex (pre-
dominantly with 1:1 stoichiometry), an aggregation process
that involves a conformational change [7–9]. Copper
homeostasis is profoundly affected in AD. The concentra-
tion of extracellular Cu(II), especially within the amyloid
plaques, is markedly elevated in AD brains [10, 11]. An ele-
vated Cu(II) concentration in the cerebrospinal fluid from
patients with AD has also been reported [12]. Micromolar
concentrations of Cu(II) induce dramatic Aβ aggregation
at a mildly acidic environment (pH 6.6), a condition that
mimics the cerebral acidosis in AD [13]. Therefore, it is
possible that excess extracellular Cu(II), via driving Aβdistributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
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between Cu(II) and monomeric Aβ are suggested to lead
to enhancement of Aβ neurotoxicity [14, 15]. It is un-
known whether these interactions modulate the effect of
Aβ on microglial activation.
The transcription factor nuclear factor (NF)-κB has
been identified as a key regulator of cellular immune re-
sponses, including microglial activation [16]. NF-κB acti-
vation can be directly driven by reactive oxygen species
(ROS) [17, 18]. ROS, derived from NADPH oxidase
(NOX) or mitochondria, play important roles in regulat-
ing microglial responses to various stimuli. ROS from
NOX may be involved in microglial activation stimulated
by fibrillar Aβ, lipopolysaccharide (LPS), or Zn(II) ions
[5, 19, 20]. On the other hand, LPS and Cu(II) are re-
ported to increase the microglial production of mito-
chondrial ROS (mtROS), which can drive the production
of proinflammatory cytokines and chemokines [21–24].
Therefore, the present study was aimed to determine
(1) whether Cu(II) coordination enhances the effect of
Aβ on microglial activation and the subsequent neuro-
toxicity, (2) whether this effect involves NF-κB and ROS,
and (3) where these ROS are generated.
Materials and methods
Chemicals
Human Aβ1–40 or Aβ1–42, dihydroethidium (DHE), Mito-
Tracker Green, and MitoSOX Red were purchased from
Invitrogen (Carlsbad, CA, USA). Mouse anti-A11 or 6E10
antibodies were from Covance (San Diego, CA, USA). CuCl2,
ZnCl2, cytosine arabinoside, pentoxifylline, aminoguanidine,
N-acetyl-cysteine (NAC), apocynin, diphenylene iodonium
(DPI), and LPS were from Sigma-Aldrich (St. Louis, MO,
USA). BAY11-7082 and SC-514 were purchased from Merck
(Darmstadt, Germany). Rabbit anti-inducible nitric oxide
synthase (iNOS), IκB-α, phospho-IκB-α, p65, phospho-
p65, β-actin, or microtubule-associated protein 2 (MAP2)
antibodies were acquired from Cell Signaling Technology
(Beverly, MA, USA). Mouse anti-CD11b antibody was
purchased from Abcam (Cambridge, MA, USA).
Preparation of Cu(II)-Aβ complex, fibrillar Aβ, and
oligomeric Aβ
Lyophilized Aβ1–40 or Aβ1–42 (1.0 mg) was dissolved in
1 ml hexafluoroisopropanol (HFIP) for 2 h at room
temperature. Then, HFIP was removed under a gentle
stream of nitrogen gas. The lyophilized peptide was dis-
solved in dimethyl sulfoxide (DMSO) to obtain a 500
μM stock solution. To generate the Cu(II)-Aβ complex,
Aβ stock solution was brought to the required concentra-
tions in 20 mM Hepes buffer (containing 153 mM NaCl;
pH 6.6) in the presence or absence of CuCl2 (with an equi-
molar Aβ:Cu(II) ratio). The reaction mixtures were incu-
bated for 24 h at 37 °C. Similarly, the Zn(II)-Aβ complexwas prepared with Aβ1–40 and ZnCl2 (with an equimolar
Aβ:Zn(II) ratio). In the cellular experiments, the Cu(II)-
Aβ or Zn(II)-Aβ complex was diluted with the culture
media to appropriate concentrations.
Fibrillar Aβ was prepared by dissolving Aβ1–40 in
ddH2O, which was followed by incubation at 37 °C for 7
days [5]. To prepare Aβ oligomers, Aβ1–40 was dissolved
to 500 μM in HFIP and was diluted to 50 μM with ddH2O.
After a 10- to 20-min incubation at room temperature, the
samples were centrifuged at 14,000×g for 15 min. The
supernatant was transferred to a new siliconized tube and
subjected to a gentle stream of nitrogen gas for 5–10 min
to evaporate the HFIP. The samples were then stirred at
500 rpm using a Teflon-coated micro stir bar for 48 h at
22 °C [25].
Aggregation assay
To determine the Cu(II)-induced Aβ aggregation, the re-
action mixtures containing 50 μM Aβ1–40 with or with-
out 50 μM Cu(II) were incubated for 24 h at 37 °C; then,
they were centrifuged at 13,000×g for 15 min to sedi-
ment aggregated proteins. The soluble peptide concentra-
tion in the supernatant was determined using Coomassie
Plus (Bradford) Assay Reagent (Thermo, Rockford, IL,
USA) [13, 26]. To quantify the amyloid fibrils, the thiofla-
vin T fluorescence assay was applied [26]. After incubation,
the samples containing Cu(II)-Aβ1–40, Aβ1–40, or fibrillar
Aβ1–40 at 50 μM peptide concentration were diluted with
50 mM glycine-NaOH buffer (pH 8.5) containing 10 μM
thioflavin T (Sigma-Aldrich) to a final volume of 100 μl.
Fluorescence was monitored using aVarioskan Flash multi-
mode reader (Thermo), with an excitation at 446 nm and
emission at 490 nm.
Dot blot
Five microliters of samples containing Cu(II)-Aβ (with
equimolar or subequimolar Aβ1–40:Cu(II) ratios) or oligo-
meric Aβ1–40 at a 10 μM peptide concentration were ap-
plied to a nitrocellulose membrane (Millipore, Bedford,
MA, USA). The membrane was air dried and then blocked
with 10 % nonfat milk in Tris-buffered saline with Tween
20 (TBST) overnight at 4 °C. Following three 5-min washes,
the membrane was incubated with A11 antibody (1:1000)
for 1 h at room temperature. After washing, the blots were
incubated with horseradish peroxidase-conjugated anti-
rabbit IgG (1:10,000, Santa Cruz, Dallas, TX, USA) for 1 h
at room temperature. The blots were detected with a
chemiluminescence kit (Pierce, Rockford, IL, USA). Then,
the same membrane was stripped and immunoblotted with
6E10 (1:1000), as described above.
Microglial cell culture
The immortalized mouse microglial cell line BV-2 was
routinely grown in Dulbecco’s modified Eagle’s medium
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with 10 % fetal calf serum (FCS; Gibco), 100 U/ml penicil-
lin, and 100 μg/ml streptomycin in a humidified atmos-
phere containing 5 % CO2 at 37 °C. Primary microglial
cultures from newborn (24 h) Sprague-Dawley pups
(Shanghai Laboratory Animal Center, Chinese Academy
of Science, Shanghai, China) were prepared as previously
described [21]. Briefly, cerebral cortex was dissected out
and minced in cold DMEM. After a 20-min trypsinization
(0.25 %), the cell suspension was centrifuged at 900×g for
10 min. The pelleted cells were resuspended and seeded
in 75-cm2 tissue culture flasks containing DMEM supple-
mented with 10 % FCS. The mixed glial cultures were
maintained at 37 °C in a humidified 5 % CO2 atmosphere,
and the medium was changed every 48 h. Once confluent
(12–14 days), the flasks were shaken (37 °C, 72 rpm) for 6
h. Microglial cells were harvested, centrifuged, and seeded
onto 96-well plates at a density of 5 × 104 cells/well.
To obtain conditioned media for treating neurons, pri-
mary microglia were first cultured in 96-well plates for
24 h in DMEM supplemented with 10 % FCS. Then,
they were washed and changed to the Neurobasal
medium with 2 % B27 supplement (Gibco) and cultured
for 24 h in the presence or absence of Cu(II)-Aβ1–40,
Aβ1–40 (preincubated at 37 °C for 24 h; if not mentioned,
the preincubated Aβ1–40 was used in the following ex-
periments), or Cu(II). The microglia-conditioned media
were collected and briefly centrifuged; then, they were
diluted with Neurobasal medium containing B27 to treat
neurons.
Primary hippocampal neuron culture
Hippocampi dissected from pups at postnatal day 1 were
used to prepare neuronal cultures as previously described
[27]. Briefly, pooled hippocampi were washed, triturated,
and then treated with papain for 20 min. The mixture was
centrifuged at 900×g for 5 min, and the precipitate was
resuspended with MEM (Gibco) containing 10 % FCS and
5 % horse serum. The cells were seeded onto a 96-well
plate at a density of 1 × 104/well. The medium was chan-
ged to Neurobasal medium with B27 supplement 4 h after
plating. To prevent the proliferation of nonneuronal cells,
cytosine arabinoside (10 μM) was added to the cultures at
the second day. Half of the medium was removed every 3
days and replaced with fresh medium. Neurons were cul-
tured for 10–14 days for experiments.
Cell viability assay
Microglial cells and hippocampal neurons were seeded onto
96-well plates and allowed to grow. When they reached the
required confluence, the medium was changed to serum-
free medium, and the cells were treated with Cu(II)-Aβ1–40,
Aβ1–40, or Cu(II) for 24 h. The survival of cells was deter-
mined by incubating the cells with a cell counting kit-8(CCK-8; 5 mg/ml; Dojindo, Kumamoto, Japan) at 37 °C
for 2 h. The absorbance was measured at a wavelength
of 450 nm. The cell viability of each treatment group
was calculated relative to the control group that was
treated with the medium. In another experiment, hip-
pocampal neurons were treated with conditioned media
from Cu(II)-Aβ1–40-stimulated microglia. The cell via-
bility was determined 24 h later.Measurement of tumor necrosis factor-α (TNF-α) and
nitric oxide production
The TNF-α concentration in the culture media of BV-2 or
primary microglial cells was determined using an enzyme-
linked immunosorbent assay kit (Pierce) according to the
manufacturer’s instructions.
Griess reagent (Sigma-Aldrich) was used to measure the
nitric oxide production. Briefly, 50 μl of medium from
each culture well was placed in triplicate wells of a 96-well
plate. An equal volume of Griess reagent was added to
each well for 10 min. The optical densities were measured
at 540 nm. The nitrite concentration was determined from
a standard curve prepared by adding NaNO2 to DMEM.Hydrogen peroxide (H2O2) assay
The production of H2O2 in BV-2 cells was quantified by a
fluorometric assay with Amplex Red reagent (Molecular
Probes, Eugene, OR, USA) according to the manufacturer’s
instructions. Briefly, the reaction mixtures in Krebs-Ringer
phosphate buffer with glucose (KRPG; 145 mM NaCl, 5.7
mM Na3PO4, 4.86 mM KCl, 0.54 mM CaCl2, 1.22 mM
MgSO4, 5.5 mM glucose, pH 7.35) containing 50 μM
Amplex Red and 0.1 U/ml horseradish peroxidase were
prewarmed at 37 °C for 10 min; then, 1 × 105 cells resus-
pended in KRPG, and Cu(II)-Aβ1–40, Aβ1–40, Cu(II), or
medium (for control group), were added. The absorbance
at 560 nm was measured at different time points using a
Varioskan Flash multimode reader (Thermo).Cytosolic and mitochondrial ROS detection
BV-2 cells were seeded in 3.5-cm cell culture dishes at a
density of 1.5 × 105/well. When the cells reached the
required confluence, they were stimulated with Cu(II)-
Aβ1–40, Aβ1–40, or Cu(II) for 1 h. Then, the cells were
washed twice with PBS and labeled at 37 °C for 30 min
with the following fluorescent probes: 0.1 μM DHE (oxi-
dized by cytosolic ROS to fluorescent ethidium that binds
nuclear DNA, Ex518 nm/Em605 nm), 200 nM MitoTracker
Green (specifically labels mitochondria, Ex490 nm/Em516 nm),
and 5 μM MitoSOX Red (specifically detects mitochondrial
superoxide, Ex510 nm/Em580 nm). The fluorescence intensity
was detected on a Nikon Eclipse 80i microscope (Melville,
NY, USA).
Fig. 1 Cu(II)-Aβ complex triggers the activation of primary microglia.
a The resting microglia (con) had branched processes, whereas
microglia incubated with Cu(II)-Aβ1–40 (at 5 μΜ peptide concentration)
for 24 h had retracted processes and a rounded morphology. Aβ1–40 and
Cu(II) alone had no obvious effect on the morphological phenotype of
microglia. Scale bar = 35 μm. b Effect of Cu(II)-Aβ on the fraction of
microglia exhibiting the activated morphology. Microglia were treated
with Cu(II)-Aβ1–40, Aβ1–40, Cu(II), or Cu(II) plus Aβ1–40 (Cu + Aβ; without
preincubation) for 24 h. The amounts of microglia with activating
morphology were counted, and the fractions of activated microglia
were calculated. Data are expressed as the means ± SEM of at least
three independent experiments. Significance was tested by one-way or
two-way ANOVA followed by Bonferroni post-test comparisons. *P < 0.05,
**P < 0.01 vs control (medium-treated); ##P < 0.01 vs Aβ or Cu(II) alone
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Primary microglial cells or hippocampal neurons were
fixed with 4 % paraformaldehyde for 1 h and blocked in
10 % BSA for 1 h at room temperature. Then, they were
stained overnight at 4 °C with mouse anti-CD11b (1:200)
or rabbit anti-MAP2 (1:50) antibodies. After incubation
with an Alexa Fluor 488 donkey anti-mouse or anti-rabbit
IgG secondary antibody (Invitrogen), cells were counter-
stained with 4′,6-diamidino-2-phenylindole (DAPI) and
imaged by a Leica TCS SP2 AOBS confocal microscope
(Leica, Wetzlar, Germany).
Western blot
BV-2 cells were plated at a density of 1.5×105 cells/ml
into 6-well plates and allowed to grow. At different time
points of Cu(II)-Aβ1–40 treatment, the cells were col-
lected and lysed with a radioimmunoprecipitation assay
(RIPA) buffer (50 mM Tris [pH 7.4], 150 mM NaCl, 1 %
Triton X-100, 1 % sodium deoxycholate, 0.1 % sodium
dodecyl sulfate [SDS], EDTA, sodium orthovanadate, so-
dium fluoride, and leupeptin) containing a protease in-
hibitor cocktail (Sigma-Aldrich). Equal amounts (30 μg)
of proteins were loaded on a 10 % SDS-PAGE gel and
transferred to polyvinylidene fluoride membranes. To
avoid nonspecific binding, the membrane was blocked with
5 % nonfat milk in TBST for 1 h at room temperature and
then incubated overnight at 4 °C with primary antibodies
specific for iNOS, phospho-IκB-α, IκB-α, phospho-p65,
p65, or β-actin at a 1:1000 dilution. The membrane was
washed three times with TBST and incubated for 1 h with
a horseradish peroxidase-conjugated secondary antibody
(1:5000; Abcam). The bands were visualized using en-
hanced chemiluminescence (Pierce).
Data analysis and statistics
Data are represented as the means ± SEM. Statistical ana-
lyses were performed using Student’s t-test and one-way
or two-way analysis of variance (ANOVA) followed by
Bonferroni post-test comparisons. Differences of P < 0.05
were considered statistically significant.
Results
Formation of the Cu(II)-Aβ complex
Incubation of Cu(II) with Aβ1–40 for 24 h at 37 °C re-
sulted in a dramatically decreased protein content in the
supernatant (P < 0.01 vs Aβ alone; Additional file 1: Figure
S1A). The results of the thioflavin T (specifically detecting
the β-sheet structure) fluorescence assay suggest that the
conformation of Cu(II)-Aβ1–40 was different from Aβ1–40
or fibrillar Aβ1–40 (Additional file 1: Figure S1B). Those of
dot blot analysis with anti-oligomer A11 antibody suggest
that the nature of Cu(II)-Aβ1–40 was different from that
of oligomeric Aβ1–40 (Additional file 1: Figure S1C).
Collectively, these data indicate that Cu(II) interactswith Aβ, which leads to the formation of the Cu(II)-Aβ
complex.
Cu(II)-Aβ complex induces microglial activation
Using the Cu(II)-Aβ1–40 complex that we prepared, we
compared its effect on microglial activation with Aβ1–40
or Cu(II) alone. The primary microglial cultures were
uniformly immunopositive for CD11b (a microglia
marker) and contained approximately 95 % microglial
cells (Additional file 2: Figure S2). The amounts of
microglia exhibiting activating morphology after Cu(II)-
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(magnification: ×100) taken with an inverted micros-
copy (EVOS FI; AMG, WA, USA) by a skilled experi-
menter who was blinded to the treatments, and the
fractions of activated microglia were calculated. Cu(II)-
Aβ1–40 treatment caused a morphological transform-
ation of microglia from the resting to active phenotype
(Fig. 1a). The increase in the number of activated
microglia was significant at 2–10 μM peptide concen-
trations of Cu(II)-Aβ1–40 (P < 0.05 or 0.01 vs control;
Fig. 1b). Whereas, the same concentrations (except 10
μM) of Aβ1–40 and Cu(II) had no obvious effect on the
morphological phenotype of microglia and the number
of activated microglia (Fig. 1a, b). Treatment with
Cu(II) plus Aβ1–40 (Cu + Aβ; without preincubation)
did not alter the number of activated microglia (Fig. 1b).
Microglial cell death was negligible when the peptide
concentrations of Cu(II)-Aβ1–40 were below 10 μM (data
not shown). We also examined the effect of Cu-Aβ1–42
and found that Cu-Aβ1–42 at a 5 μM peptide concentra-
tion elicited an increased fraction of activated microglia
(74.3 ± 4.6 %; P < 0.01 vs control [32.3 ± 3.4 %], Aβ1–42
[44.2± 3.8 %], or Cu(II) [38.9 ± 3.6 %]; n = 3).
Cu(II)-Aβ complex induces TNF-α production in microglial
cells
TNF-α concentrations in the media of primary micro-
glial cultures and BV-2 cells were increased in a dose-
dependent manner after Cu(II)-Aβ1–40 stimulation, andFig. 2 TNF-α concentration in the media from microglial cells. Primary (a) and B
peptide concentrations), Aβ1–40, or Cu(II) for 24 h. c BV-2 cells were stimulated w
Cu(II), or Zn(II) for 24 h. d BV-2 cells were stimulated with Cu(II)-Aβ1–40 or Cu(II)-A
Aβ1–40 or Aβ1–42 (Cu + Aβ40 or Cu + Aβ42; without preincubation) for 24 h. Da
experiments. Significance was tested by one-way or two-way ANOVA followe
#P < 0.05, ##P < 0.01 vs Aβ, Cu(II), or Zn(II) aloneTNF-α production induced by 5–10 μM of Cu(II)-Aβ1–40
was more robust than that induced by Aβ1–40 or Cu(II)
alone (P < 0.01); Aβ1–40 and Cu(II) at 1–5 μM had no obvi-
ous effect on the TNF-α content; while at 10 μM, they in-
duced significantly increased TNF-α production (P < 0.05
vs control; Fig. 2a, b). Zn(II) can also bind to Aβ to form
Zn(II)-Aβ complex [9]. So, we also examined the effect of
Zn(II)-Aβ1–40 on microglial release of TNF-α. We found
that Zn(II)-Aβ1–40 caused similar TNF-α production to
that induced by Cu(II)-Aβ1–40 in BV-2 cells (Fig. 2c). In
addition, Cu(II)-Aβ1–42 also elicited microglial release of
TNF-α in BV-2 cells (Fig. 2d). Treatment with addition of
Cu(II) and Aβ without preincubation had little effect on
TNF-α production in BV-2 cells (Fig. 2d).
Cu(II)-Aβ complex induces nitric oxide production in
microglial cells
Next, we examined the nitric oxide production in micro-
glial cells. Cu(II)-Aβ1–40 treatment led to significantly in-
creased nitric oxide content in the media from both
primary and BV-2 microglial cells, as evaluated by meas-
uring the concentration of nitrite (NO2
−), its stable
metabolite; whereas, Aβ1–40 or Cu(II) alone had no obvi-
ous effect on the nitrite content (Fig. 3a, b). In parallel,
Western blot analysis with BV-2 cells revealed an induc-
tion of iNOS expression in response to Cu(II)-Aβ1–40
stimulation, which was prominent at 24 h (Fig. 3c). Aβ1–40
or Cu(II) alone had no obvious effect on the iNOS expres-
sion (Additional file 3: Figure S3).V-2 (b) microglial cells were stimulated with Cu(II)-Aβ1–40 (at 1–10 μΜ
ith Cu(II)-Aβ1–40 or Zn(II)-Aβ1–40 (at 5 μΜ peptide concentration), Aβ1–40,
β1–42 (at 5 μΜ peptide concentration), Aβ1–40 or Aβ1–42, Cu(II), or Cu(II) plus
ta are expressed as the means ± SEM of at least three independent
d by Bonferroni post-test comparisons. *P < 0.05, **P < 0.01 vs control;
Fig. 3 Nitric oxide concentration in the media from primary (a) and BV-2
(b) microglial cells. Microglial cells were stimulated with Cu(II)-Aβ1–40 (5 μΜ
peptide), Aβ1–40, or Cu(II) for 24 h. Data are expressed as the means ± SEM
of at least three independent experiments. Significance was tested
by one-way ANOVA followed by Bonferroni post-test comparisons.
*P < 0.05 vs control; #P < 0.05 vs Cu-Aβ. c Western blot analysis of
iNOS expression in BV-2 cells after Cu(II)-Aβ stimulation
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microglia
We first examined whether Cu(II)-Aβ1–40 causes direct
neuronal damage at doses required for activating micro-
glia. Cu(II)-Aβ1–40, at 1–5 μM peptide concentrations,
did not cause obvious neuronal death (Fig. 4a). Next, we
activated cultured primary microglia using a subneuro-
toxic concentration (5 μM) of Cu(II)-Aβ1–40 and trans-
ferred the microglia-conditioned media (Cu-Aβ-CM) to
neuronal cultures. In the meantime, we treated neurons
with conditioned media derived from microglia treated
with solvent (con-CM, used as negative controls), Aβ1–40
(5 μM; Aβ-CM), Cu(II) (5 μM; Cu-CM), or media with
Cu(II)-Aβ1–40 but without being conditioned by microglia(Cu-Aβ). Cu-Aβ-CM reduced neuronal survival in a dose-
dependent manner (P < 0.01 vs con-CM at 25–50 % of
media). Whereas, the equivalent amount of con-CM, Aβ-
CM, Cu-CM, or Cu-Aβ directly added to the media with-
out being conditioned by microglia did not reduce the
neuronal viability (Fig. 4b). We used Triton X-100 (at 100
μM), which results in the necrotic death of the cells [28],
as a cell death control for the cell viability assay. We found
that the viability of Triton X-treated neurons was less than
10 % (9.6 ± 2.1 %; n = 3).
Dendritic damage is an important pathological process
in neuronal loss in AD. To further confirm the indirect
neurotoxicity produced by Cu(II)-Aβ1–40, we stained the
neuronal dendrites with an antibody against MAP2, a
dendritic marker. We found that neurons treated with
Cu-Aβ-CM had markedly dendritic damage than those
treated with con-CM (Fig. 4c). Aβ1–40 or Cu(II) alone
had no obvious effect on the MAP2 immunofluores-
cence (data not shown).TNF-α and nitric oxide are involved in Cu(II)-Aβ
complex-caused, microglia-mediated neurotoxicity
Subsequently, we examined the effect of inhibiting micro-
glial production of TNF-α and nitric oxide with pentoxifyl-
line, a nonselective phosphodiesterase inhibitor that blocks
the release of TNF-α from microglia and does not affect
nitrite accumulation [29], and aminoguanidine, an iNOS in-
hibitor. We found that the conditioned media from micro-
glia treated with pentoxifylline plus aminoguanidine (but
not pentoxifylline or aminoguanidine alone) in the presence
of Cu(II)-Aβ1–40 induced less neuronal death than the con-
ditioned media from microglia treated with Cu(II)-Aβ1–40
(P < 0.05; Fig. 5). Pentoxifylline or aminoguanidine did not
affect neuronal survival (data not shown).
NF-κB is required for Cu(II)-Aβ complex-induced
microglial activation
NF-κB activation is critical for cellular inflammatory re-
sponses, such as microglial activation [16, 30]. There-
fore, we investigated whether NF-кB is involved in Cu(II)-
Aβ1–40-primed microglial activation. Both BAY11-7082
and SC-514, the inhibitors for IκB-α phosphorylation and
IκB kinase-2 (IKK-2), respectively, abrogated Cu(II)-Aβ1–40-
induced TNF-α or nitric oxide production in BV-2 cells
(Fig. 6a, b). In parallel, Western blot analysis revealed that
Cu(II)-Aβ1–40 treatment induced phosphorylation and deg-
radation of IκB-α protein as well as phosphorylation of NF-
кB p65 (Fig. 6c).
Cu(II)-Aβ complex induces NOX-independent extracellular
H2O2 release
ROS, such as H2O2, are critical for regulating the glial in-
flammatory response to various stimuli [20]. We detected
H2O2 release induced by Cu(II)-Aβ1–40 using a fluorometric
Fig. 4 Cu(II)-Aβ complex causes indirect, microglia-mediated neurotoxicity. a Cell viability of hippocampal neurons treated with Cu(II)-Aβ1–40 (1–10 μΜ
peptide), Aβ1–40, or Cu(II) for 24 h. b Conditioned media (CM) from microglia stimulated with Cu(II)-Aβ1–40 (5 μΜ peptide, 24 h) caused neurotoxicity.
Hippocampal neurons were treated with five types of media diluted into the neuronal culture media at indicated percentiles for 24 h. They are (1)
media with direct addition of Cu(II)-Aβ1–40 (5 μM peptide), (2) media previously conditioned by unstimulated microglia (con-CM), (3) media previously
conditioned by Aβ1–40-stimulated microglia (Aβ-CM), (4) media previously conditioned by Cu(II)-stimulated microglia (Cu-CM), and (5) media previously
conditioned by Cu(II)-Aβ1–40-stimulated microglia (Cu-Aβ-CM). Data are expressed as the means ± SEM of at least three independent experiments.
Significance was tested by one-way or two-way ANOVA followed by Bonferroni post-test comparisons. *P < 0.05, **P < 0.01 vs control (a) or con-CM
(b); #P < 0.05 vs Aβ-Cu-CM. c Cu(II)-Aβ1–40 caused indirect, microglia-mediated damage to neuronal dendrites. All CM used were diluted at 50 % into
the neuronal culture media. The control group was treated with solvent only. Neuronal dendrites were observed by immunostaining for MAP2 (green)
Yu et al. Journal of Neuroinflammation  (2015) 12:122 Page 7 of 11assay with Amplex Red. Cu(II)-Aβ1–40 stimulation led
to a rapid accumulation of H2O2 in the culture media
of BV-2 cells, while Aβ1–40 or Cu(II) alone had no obvi-
ous effect on H2O2 production (Fig. 7a). We then used
two NOX inhibitors, apocynin and DPI, to determine
whether the H2O2 is derived from NOX. Neither apocy-
nin nor DPI affected H2O2 release elicited by Cu(II)-Fig. 5 TNF-α and nitric oxide are involved in Cu(II)-Aβ complex-caused,
microglia-mediated neurotoxicity. Cell viability of hippocampal neurons
treated with conditioned media (CM, at 50 % of neuronal culture media)
from primary microglia stimulated with Cu(II)-Aβ1–40 (5 μΜ peptide) in
the presence or absence of pentoxifylline (PTX, 1 mM) and/or
aminoguanidine (AG, 200 μM). Data are expressed as the means ± SEM
of at least three independent experiments. Significance was tested by
one-way ANOVA followed by Bonferroni post-test comparisons.
**P < 0.01 vs con-CM; #P < 0.05 vs Cu-Aβ-CMAβ1–40 (Fig. 7b). In addition, Cu(II)-Aβ1–40 was unable
to evoke extracellular superoxide release (Fig. 7c).
Cu(II)-Aβ complex induces mitochondrial superoxide
production
Mitochondria are another intracellular source of ROS
apart from NOX [31, 32]. Therefore, we detected mtROS
production using MitoSOX, a fluorogenic dye that can
be oxidized by superoxide and used as a mitochondrial
superoxide indicator of live cells. Overlay images of cells
labeled with MitoSOX Red and MitoTracker Green indi-
cate that mitochondria are the primary site of ROS pro-
duction in Cu(II)-Aβ1–40-stimulated BV-2 cells (Fig. 8a).
Next, we labeled the cytosolic ROS with DHE and noted
a significant increase in DHE fluorescence in cells stimu-
lated with Cu(II)-Aβ1–40 (Fig. 8b). Aβ1–40 or Cu(II) at 5 μM
had no obvious effect on the cytosolic or mitochondrial
superoxide production (data not shown).
ROS are involved in Cu(II)-Aβ complex-induced microglial
activation and the indirect neurotoxicity
We treated BV-2 cells with Cu(II)-Aβ1–40 in the presence of
NAC, a ROS scavenger. NAC inhibited the Cu(II)-Aβ1–40-
induced microglial release of TNF-α and nitric oxide
(Fig. 9a, b). Moreover, the conditioned media from primary
microglia incubated with NAC in the presence of Cu(II)-
Aβ1–40 failed to cause obvious neuronal death (Fig. 9c).
NAC had no effect on neuronal survival (data not shown).
Fig. 6 Cu(II)-Aβ complex-induced microglial activation depends on NF-κB. a, b BAY11-7082 and SC-514 inhibited Cu(II)-Aβ1–40-induced release of
TNF-α or nitric oxide. BV-2 cells were pretreated with BAY11-7082 (10 μΜ) or SC-514 (50 μΜ) for 1 h prior to 24-h stimulation with Cu(II)-Aβ1–40
(5 μΜ peptide). Data are expressed as the means ± SEM of at least three independent experiments. Significance was tested by one-way ANOVA
followed by Bonferroni post-test comparisons. *P < 0.05, **P < 0.01 vs control; #P < 0.05 vs Cu-Aβ. c The phosphorylation and degradation of
IкB-α and phosphorylation of p65 in BV-2 cells stimulated with Cu(II)-Aβ1–40. The cells were treated with Cu(II)-Aβ for indicated time intervals
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Our data show for the first time that Cu(II) enhances the
effect of Aβ on microglial activation and the subsequent
neurotoxicity. This activating effect is NF-κB-dependent and
involves NOX-independent, mitochondria-derived ROS.
Cu(II) is suggested to bind monomeric Aβ peptides
(predominantly with 1:1 stoichiometry) with high affinity,
leading to the formation of Cu(II)-Aβ complex [7–9]. In
the present study, the results of an assay of Aβ aggregation
by sedimentation, thioflavin T fluorescence assay, and dot
blot analysis indicate the formation of Cu(II)-Aβ complex,
whose conformation or nature differs from fibrillar or
oligomeric Aβ and monomeric Aβ.
In the following experiments, we found that Cu(II)-Aβ
induced an activating morphological phenotype of micro-
glia and microglial release of TNF-α and nitric oxide. TheFig. 7 Cu(II)-Aβ complex induces NADPH oxidase-independent extracellula
stimulation with Cu(II)-Aβ1–40 (5 μM peptide), Aβ1–40, or Cu(II). b H2O2 concen
the presence or absence of apocynin (100 μΜ) or DPI (10 μΜ). c Cu(II)-Aβ1–40
release. Data are expressed as the means ± SEM of at least three independen
followed by Bonferroni post-test comparisons. *P < 0.05, **P < 0.01 vs controlincrease in nitric oxide production was accompanied by
an increase in iNOS expression. Moreover, a subneuro-
toxic concentration of Cu(II)-Aβ produced an indirect,
microglia-mediated neurotoxicity, as demonstrated by the
impaired neuronal viability and dendritic damage. Import-
antly, Aβ or Cu(II) alone induced neither the microglial
release of soluble neurotoxic factors nor the microglia-
mediated neurotoxicity. Therefore, it is likely that the
interactions between Cu(II) and Aβ lead to enhancement
of the Aβ effect on microglial activation. In contrast to the
observations that either neutralization of TNF-α or inhib-
ition of iNOS is sufficient to prevent neurotoxicity pro-
duced by aggregated Aβ-activated microglia [29, 33], we
found that repression of microglial release of both TNF-α
and nitric oxide, but not of TNF-α or nitric oxide alone, was
protective for hippocampal neurons. These data indicate thatr H2O2 release. a H2O2 concentration in the media from BV-2 cells after
tration in the media from BV-2 cells treated with Cu(II)-Aβ1–40 (for 1 h) in
stimulation (for 1 h) had no obvious effect on extracellular superoxide
t experiments. Significance was tested by one-way or two-way ANOVA
; ##P < 0.01 vs Aβ or Cu(II) alone
Fig. 8 Cu(II)-Aβ complex induces mitochondrial superoxide production
in BV-2 cells. a Overlay images of cells stained with MitoSOX Red
(red, detects mitochondrial ROS) and MitoTracker Green (green,
localizes to mitochondria) after Cu(II)-Aβ1–40 (5 μM peptide) stimulation
for 1 h. b Cytosolic ROS were stained with a fluorescent probe
dihydroethidium after Cu(II)-Aβ1–40 stimulation for 1 h. LPS (1 μg/ml)
was used as positive control. Bar = 100 μm
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lated microglia need to act synergistically to elicit neur-
onal damage.
NF-κB is an important regulator of the gene expres-
sion of proinflammatory mediators. The inhibitory IκB-α
can be phosphorylated by activated IKK and then de-
graded, leading to phosphorylation and translocation of
p65 and activation of gene transcription. In the present
study, the inhibitors of IκB-α phosphorylation and IKK-2
prevented the Cu(II)-Aβ-induced microglial release of
TNF-α and nitric oxide, suggesting that the actions of
Cu(II)-Aβ depend on NF-кB. Cu(II)-Aβ stimulation also
induced phosphorylation and degradation of IкB-α asFig. 9 Effects of NAC on Cu(II)-Aβ complex-induced microglial activation and th
media from BV-2 cells treated with Cu(II)-Aβ1–40 (5 μΜ peptide) for 24 h with or
conditioned media (CM, at 50 % of neuronal culture media) from primary micro
are expressed as the means ± SEM of at least three independent experiments. S
post-test comparisons. *P < 0.05, **P < 0.01 vs control (a, b) or con-CMwell as phosphorylation of p65, further confirming the
involvement of NF-кB.
ROS are critical for microglial activation [20, 34]. We
found that Cu(II)-Aβ (but not Aβ or Cu(II) alone) trig-
gered extracellular H2O2 accumulation. NOX, an enzyme
that catalyzes the production of superoxide, is a producer
of extracellular and intracellular ROS. We found that the
NOX inhibitors did not affect Cu(II)-Aβ-induced H2O2
production. Furthermore, Cu(II)-Aβ was unable to evoke
superoxide release. These data indicate that Cu(II)-Aβ-
elicited extracellular H2O2 is not from NOX.
Mitochondria serve as another major source of ROS in
most cells [31, 32]. Mitochondrion-generated superoxide,
which does not cross the inner membrane, can be con-
verted to membrane-permeable H2O2 by matrix Mn-
superoxide dismutase, and H2O2 can diffuse to the cytosol
and extracellular space (thus can be detected in the culture
media) [35]. We observed an accumulation of mtROS in
BV-2 cells stimulated with Cu(II)-Aβ. Given the finding
that Cu(II)-Aβ-elicited extracellular H2O2 is not from
NOX, it is likely that H2O2 originates in the mitochondria.
In the meantime, cytosolic ROS accumulated in cells stimu-
lated with Cu(II)-Aβ, indicating that some mtROS were dif-
fused to cytosol. There is evidence that mtROS can diffuse
to cytosol to signal NF-кB activation and proinflammatory
cytokine expression [17, 22]. Therefore, our results strongly
suggest that mtROS are involved in Cu(II)-Aβ-triggered
microglial activation. Our findings that H2O2 release due to
Cu(II)-Aβ stimulation is NOX-independent seem to be in
contrast to those that fibrillar Aβ, LPS, or Zn(II) evokes
NOX-dependent ROS production [5, 19, 20]. However, we
noticed that, similar to the recent findings of Park et al.
[23] and Voloboueva et al. [24], LPS elicited robust mtROS
production. Therefore, microglial activation upon in-
flammatory stimulations may involve both NOX- and
mitochondrion-derived ROS.
Noteworthy, we found that NAC (a ROS scavenger that
readily passes into cells) inhibited the Cu(II)-Aβ-elicited
microglial release of TNF-α and nitric oxide as well as
microglia-mediated neuronal death. These results suggeste indirect neurotoxicity. TNF-α (a) and nitric oxide (b) concentration in the
without NAC (1 mM). c Cell viability of hippocampal neurons treated with
glia stimulated with Cu(II)-Aβ1–40 in the presence or absence of NAC. Data
ignificance was tested by one-way ANOVA followed by Bonferroni
(c); #P < 0.05 vs Cu-Aβ (a, b) or Cu-Aβ-CM (c)
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uble neurotoxic factors. Oxidative stress, an early event in
AD pathogenesis, plays a critical role in neuronal dysfunc-
tion and death in this disease [36, 37]. Studies with murine
models provide supportive evidence that administration of
NAC blocks oxidative damage in AD [38, 39]. Clinical tri-
als also show that NAC treatment is potentially beneficial
to AD patients [38–41]. Our findings that NAC amelio-
rates neuronal injury mediated by Cu(II)-Aβ-activated
microglia may further warrant the use of NAC in AD
therapy.
In our work, preincubated (37 °C for 24 h) Aβ alone (up
to 5 μM) had little effect on microglial activation. We no-
ticed that the structure of these Aβ peptides is neither
oligomeric nor fibrillar, which may be one explanation for
this observation. Aβ can be taken up by microglia [42]. So,
it is possible that Cu(II)-Aβ is taken up by microglial cells
to induce mtROS production and that the difference in
potency for microglial activation between Cu(II)-Aβ and
Aβ is due to uptake difference.
The role of microglia in the pathogenesis of AD might
be switched from a beneficially phagocytic effect to a pro-
inflammatory cytotoxic role (with the classic M1 pheno-
type) with the age-dependent accumulation of extracellular
Aβ aggregates [43]. At the early stage of AD, microglia
might play a modulatory role via phagocytosis of Aβ pla-
ques. In addition, microglia may exert protective functions
through intracellular Cu(II) sequestration, which may pre-
vent further plaque formation [44].
Interestingly, recent evidence shows that Cu(I), which
also promotes Aβ aggregation [45], may polarize inflamed
microglial populations from the neurotoxic (M1) pheno-
type to the neuroprotective (M2) phenotype via inhibition
of nitric oxide production [46]. This observation impli-
cates that the valence state of copper may be important in
the regulation of microglial phenotype. The microglial re-
sponses to Cu(I)-Aβ and Cu(II)-Aβ and the subsequent
neurotoxicity might be different as a result of their differ-
ent redox capability.
Taken together, the present study identifies Cu(II) as a
cofactor that promotes the effect of Aβ on microglial acti-
vation and the subsequent neurotoxicity. Moreover, the
Cu(II)-Aβ-triggered microglial activation may involve NF-
кB activation and mtROS production. These findings sup-
port the notion that metal ion-induced Aβ aggregation
might be important in microglia-mediated neuroinflam-
mation and might provide a novel anti-inflammatory strat-
egy for AD.
Additional files
Additional file 1: Figure S1. Formation of the Cu(II)-Aβ complex. (A)
Peptide concentration in the supernatant of reaction mixtures containing
Aβ1–40 (50 μM) with or without Cu(II) (50 μM). (B) Effect of Cu(II) on theformation of Aβ fibrils. The amyloid fibril formation of Aβ1–40 in the presence
of Cu(II) (50 μM) was determined using the thioflavin T (ThT) fluorescence
assay. Fibrillar Aβ1–40 (Aβf, 50 μM) was used as a positive conference. Data are
expressed as the means ± SEM of three independent experiments.
Significance was tested by Student’s t-test. **P < 0.01 vs Aβ (A) or Aβf
(B); #P < 0.05 vs Aβ (B). (C) Dot blot analysis of Aβ1–40 and Cu(II)-Aβ1–40
(with 1:1 or 1:2 of Aβ:Cu(II) molar ratios) at a peptide concentration of
10 μM. Aβ1–40 was incubated in 20 mM Hepes buffer (containing 153
mM NaCl; pH 6.6) in the presence or absence of Cu(II) for 24 h at 37 °C.
Oligomeric Aβ1–40 (Aβo) was used as a positive control.
Additional file 2: Figure S2. Characterization of the microglial culture
purity. Microglial cultures were immunostained with the microglial
marker CD11b. Scale bar = 300 μm.
Additional file 3: Figure S3. Western blot analysis of iNOS expression
in BV-2 cells. (A) Representative Western blots of iNOS in BV-2 cells after
Cu(II)-Aβ1–40 (at 5 μΜ peptide concentration), Cu(II), or Aβ1–40 stimulation
(for 24 h). (B) Densitometric analysis of iNOS/β-actin ratio normalized to
saline control. n = 3 experiments. **P < 0.01 vs con; #P < 0.05 vs Cu-Aβ.
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